LFMD Stock - LifeMD, Inc.
Unlock GoAI Insights for LFMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $212.45M | $152.55M | $119.03M | $92.88M | $37.29M |
| Gross Profit | $188.39M | $133.65M | $100.37M | $74.88M | $28.43M |
| Gross Margin | 88.7% | 87.6% | 84.3% | 80.6% | 76.2% |
| Operating Income | $-16,144,681 | $-14,489,273 | $-43,447,781 | $-54,301,081 | $-57,819,453 |
| Net Income | $-18,881,732 | $-20,595,992 | $-45,535,659 | $-60,897,704 | $-58,646,943 |
| Net Margin | -8.9% | -13.5% | -38.3% | -65.6% | -157.3% |
| EPS | $-0.53 | $-0.70 | $-1.45 | $-2.27 | $-4.24 |
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 18th 2025 | BTIG Research | Reiterated | Buy | $18← $15 |
| December 10th 2024 | Lake Street | Initiation | Buy | $12 |
| December 4th 2024 | Mizuho | Initiation | Neutral | $7 |
| August 23rd 2024 | B. Riley Securities | Resumed | Buy | $11 |
| June 5th 2024 | KeyBanc Capital Markets | Initiation | Overweight | $12 |
| November 30th 2023 | Craig Hallum | Initiation | Buy | $10 |
| July 21st 2023 | Cantor Fitzgerald | Initiation | Overweight | $7 |
| July 3rd 2023 | H.C. Wainwright | Initiation | Buy | $9 |
Earnings History & Surprises
LFMDEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | $-0.01 | — | — | — |
Q4 2025 | Nov 17, 2025 | $-0.06 | $-0.10 | -66.7% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $0.18 | $-0.05 | -126.0% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.04 | $0.01 | +125.0% | ✓ BEAT |
Q1 2025 | Mar 10, 2025 | $-0.04 | $-0.02 | +50.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.10 | $-0.14 | -40.0% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.13 | $-0.19 | -46.2% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.13 | $-0.19 | -46.2% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.14 | $-0.12 | +14.3% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.09 | $-0.23 | -155.6% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-0.16 | $-0.15 | +6.3% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.18 | $0.02 | +111.1% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.27 | $-0.03 | +88.9% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-0.26 | $-0.25 | +3.8% | ✓ BEAT |
Q1 2022 | Mar 7, 2022 | $-0.39 | $-0.29 | +25.6% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.49 | $-0.36 | +26.5% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.45 | $-0.51 | -13.3% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $9
➖ NeutralKeybanc Maintains Overweight on LifeMD, Lowers Price Target to $8
➖ NeutralMizuho Maintains Neutral on LifeMD, Lowers Price Target to $6
➖ NeutralLake Street Maintains Buy on LifeMD, Lowers Price Target to $8
➖ NeutralB. Riley Securities Maintains Buy on LifeMD, Lowers Price Target to $10
➖ NeutralLifeMD shares are trading lower after the company reported worse-than-expected Q3 financial results and issued Q4 sales guidance below estimates. Also, company cut its FY25 sales guidance below estimates.
📉 NegativeBTIG Maintains Buy on LifeMD, Lowers Price Target to $10
📈 PositiveLifeMD plunges following quarterly misses, updated guidance
📉 NegativeLifeMD shares are trading lower after the company reported worse-than-expected Q3 financial results and issued Q4 sales guidance below estimates. Also, company cut its FY25 sales guidance below estimates.
📉 NegativeLifeMD Lowers FY2025 Sales Guidance from $268.000M-$275.000M to $192.000M-$193.000M vs $253.075M Est
📉 NegativeLifeMD Sees Q4 Sales $45.000M-$46.000M vs $63.070M Est
📉 NegativeLifeMD Q3 Adj. EPS $(0.07) Misses $(0.05) Estimate, Sales $60.172M Miss $62.064M Estimate.
📉 NegativeLifeMD To Offer 0.25 mg and 0.5 mg Doses Of Wegovy And Ozempic At $199/Month
📈 PositiveLifeMD Sells Majority Stake In WorkSimpli For ~$65M
📈 PositiveLifeMD Expands Novo Nordisk Collaboration To Offer Ozempic Access At $499/Month
📈 PositiveLifeMD To Offer Ozempic At $499/Month Through NovoCare Integration
📈 PositiveLifeMD Expands Affiliated Pharmacy To Include Advanced Non-Sterile Compounding Capabilities For Oral And Topical Medications
📈 PositiveFrequently Asked Questions about LFMD
What is LFMD's current stock price?
What is the analyst price target for LFMD?
What sector is LifeMD, Inc. in?
What is LFMD's market cap?
Does LFMD pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LFMD for comparison